Table 3. Univariate and multivariable analysis of overall survival in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT.
| Characteristics | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| aCervical esophageal SCC group | ||||
| Neutrophil lymphocyte ratio ≥ 2.5 | 2.19 (1.14–4.20) | 0.019* | ||
| Platelet lymphocyte ratio ≥ 103 | 2.51 (1.22–5.17) | 0.013* | 2.66 (1.27–5.58) | 0.010* |
| Albumin ≥ 3.5 | 0.70 (0.31–1.61) | 0.404 | ||
| CRP >10 | 1.95 (1.03–3.69) | 0.037* | ||
| mGPS ≥ 1 | 1.95 (1.03–3.69) | 0.037* | 2.03 (1.07–3.86) | 0.030* |
| CRP/Albumin ratio ≥ 9.5 | 1.96 (1.06–3.64) | 0.033* | ||
| aThoracic esophageal SCC group | ||||
| Neutrophil lymphocyte ratio ≥ 2.5 | 1.87 (1.03–3.42) | 0.041* | 2.21 (1.19–4.12) | 0.012* |
| Platelet lymphocyte ratio ≥ 103 | 1.89 (1.09–3.28) | 0.024* | ||
| Albumin ≥ 3.5 | 0.68 (0.35–1.32) | 0.246 | ||
| CRP >10 | 2.78 (1.50–5.15) | 0.001* | ||
| mGPS ≥ 1 | 2.78 (1.50–5.15) | 0.001* | 3.13 (1.66–5.88) | <0.001* |
| CRP/Albumin ratio ≥9.5 | 2.42 (1.38–3.24) | 0.002* | ||
Notes.
- CCRT
- concurrent chemoradiotherapy
- HR
- hazard ratio
- CI
- confidence interval
- CRP
- C-reactive protein
- mGPS
- modified Glasgow Prognostic Score
a
Using propensity score matching method.
*
Statistically significant.